about
The prothrombotic tendency in metabolic syndrome: focus on the potential mechanisms involved in impaired haemostasis and fibrinolytic balanceHigh prevalence of nonalcoholic fatty liver in patients with idiopathic venous thromboembolism.Lack of association between Ser(413)/Cys polymorphism of plasminogen activator inhibitor type 2 (PAI-2) and premature coronary atherosclerotic diseaseLack of association between polymorphisms of thrombogenic genes and disease susceptibility in rheumatoid arthritis.Decrements in the thrombin activatable fibrinolysis inhibitor (TAFI) levels in association with orlistat treatment in obesity.
P2860
description
1999 nî lūn-bûn
@nan
1999 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Fibrinolytic function and coronary risk.
@ast
Fibrinolytic function and coronary risk.
@en
Fibrinolytic function and coronary risk.
@nl
type
label
Fibrinolytic function and coronary risk.
@ast
Fibrinolytic function and coronary risk.
@en
Fibrinolytic function and coronary risk.
@nl
prefLabel
Fibrinolytic function and coronary risk.
@ast
Fibrinolytic function and coronary risk.
@en
Fibrinolytic function and coronary risk.
@nl
P2093
P1476
Fibrinolytic function and coronary risk.
@en
P2093
Christine Alessi M
Juhan-Vague I
P2888
P304
P356
10.1007/S11886-999-0069-X
P577
1999-07-01T00:00:00Z
P6179
1047595241